Our corporate workshop will illustrate how rapid multiplex molecular research tools could contribute to the optimal management of leukemia patients in the future from risk-based classification at initial diagnosis to monitoring of residual disease with an emphasis on:

Moderated by: Dr. Emmanuel Labourier

Kathleen Murphy, Ph.D.

Kathleen Murphy, Ph.D., is the Director of Clinical Laboratory Operations at ProPath. Dr. Murphy holds a Ph.D. in microbiology and immunology from the University of Louisville and a B.S. in medical technology from George Mason University. She completed her postdoctoral fellowship in molecular pathology at Johns Hopkins University School of Medicine. Prior to joining ProPath, Dr Murphy was Associate Professor and Director of JHU’s Molecular Diagnostic Laboratory. Dr. Murphy has won numerous awards and honors including the Young Investigator Award from AMP in 2001. Dr. Murphy is a reviewer for many well-known journals and has authored or co-authored over 65 peer reviewed publications, including about half a dozen on the topic of BCR-ABL1 testing.

Guido Marcucci, M.D.

Guido Marcucci, M.D., is Professor of medicine and the John B. and Jane T. McCoy Chair in Cancer Research in the Division of Hematology at the Ohio State University (OSU) and the Associate Director of Translational Research at the OSU Comprehensive Cancer Center. Dr. Marcucci chairs the Alliance (former CALGB) Leukemia Correlative Science Committee. He obtained his M.D. from Catholic University of the Sacred Heart, Rome, Italy. He completed his residency in internal medicine at the State University of New York and his fellowship in clinical oncology at Roswell Park Cancer Institute. Dr Marcucci’s research and clinical interests are focused on biology, drug development and prognostic assessment of acute leukemias.

Li Cai, Ph.D.

Li Cai, Ph.D., is the Discipline Director of Molecular Oncology, Center for Molecular Biology and Pathology at Laboratory Corporation of America (LabCorp). Dr Cai holds a Ph.D. in genetics from Texas A&M University and a BS in genetics and animal breeding from Beijing Agricultural University. She received her medical genetics training in clinical molecular genetics from Harvard Medical School. She is board-certified in clinical molecular genetics by the American Board of Medical Genetics and holds certification in molecular genetic testing and oncology from the New York State Department of Health. She received the National Institutes of Health Individual Research Award for her work on cloning the PXE gene during her fellowship at Harvard Medical School. She has authored numerous peer-reviewed publications and holds patents for her gene discovery research.

AMP Early Bird Session: Friday November 18, 2011
7:00-7:45 AM

Advancements in FMR1 Methylation PCR

Fragile X testing currently requires Southern blot analysis to resolve the methylation status of expanded alleles. However, this method is time-consuming, low throughput, low resolution, and requires large inputs of specimen DNA. In this session, we will describe recent progress in the development and evaluation of PCR technologies with the potential to address these limitations.